{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:17:32Z","timestamp":1790331452298,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.2515\/therapie\/2010017","type":"journal-article","created":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T13:51:23Z","timestamp":1281448283000},"page":"213-218","source":"Crossref","is-referenced-by-count":10,"title":["Niveau de preuve du suivi th\u00e9rapeutique pharmacologique des inhibiteurs de tyrosine-kinase dans le traitement des leuc\u00e9mies my\u00e9lo\u00efdes chroniques"],"prefix":"10.1016","volume":"65","author":[{"given":"St\u00e9phane","family":"Bouchet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Le Guellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Titier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2010017_bb0005","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2007.13.1128","article-title":"Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity","volume":"26","author":"Rudin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie\/2010017_bb0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clpt.2006.04.007","article-title":"Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer","volume":"80","author":"Lu","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2010017_bb0015","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2165\/00003495-200767170-00013","article-title":"Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"67","author":"Cross","year":"2007","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2010017_bb0020","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie\/2010017_bb0025","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0030","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0035","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0040","first-page":"447","article-title":"Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronicphase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (tyrosine kinase dose optimization study [TOPS])","volume":"112","author":"Guilhot","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.2515\/therapie\/2010017_bb0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"Forrest","year":"2009","journal-title":"Leuk Res"},{"key":"10.2515\/therapie\/2010017_bb0050","first-page":"4269","article-title":"Imatinib trough plasma concentration and its correlation with clinical response in chronic phase and accelerated phase of CML","volume":"112","author":"Foryciarz","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.2515\/therapie\/2010017_bb0055","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0060","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2007-03-079871","article-title":"Therapeutic drug monitoring in CML patients on imatinib","volume":"110","author":"Blasdel","year":"2007","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0065","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability","volume":"98","author":"Widmer","year":"2008","journal-title":"Br J Cancer"},{"key":"10.2515\/therapie\/2010017_bb0070","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0075","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie\/2010017_bb0080","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0085","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jat\/31.6.334","article-title":"Quantification of eight new antidepressants and five of their active metabolites in whole blood by highperformance liquid chromatography-tandem mass spectrometry","volume":"31","author":"Castaing","year":"2007","journal-title":"J Anal Toxicol"},{"key":"10.2515\/therapie\/2010017_bb0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie\/2010017_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","article-title":"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects","volume":"53","author":"Bolton","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.2515\/therapie\/2010017_bb0100","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1200\/JCO.2005.03.2185","article-title":"Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme","volume":"23","author":"Reardon","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.2515\/therapie\/2010017_bb0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clpt.2004.06.007","article-title":"Effect of St John\u2019s wort on imatinib mesylate pharmacokinetics","volume":"76","author":"Frye","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2010017_bb0110","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1592\/phco.24.16.1508.50958","article-title":"The influence of St. John\u2019s wort on the pharmacokinetics and protein binding of imatinib mesylate","volume":"24","author":"Smith","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.2515\/therapie\/2010017_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2010017_bb0120","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population pharmacokinetics and pharmacogenetics of imatinib in children and adults","volume":"14","author":"Petain","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.2515\/therapie\/2010017_bb0125","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","article-title":"Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults","volume":"63","author":"Menon-Andersen","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.2515\/therapie\/2010017_bb0130","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0135","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","article-title":"Interaction of imatinib mesilate with human P-glycoprotein","volume":"307","author":"Hamada","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.2515\/therapie\/2010017_bb0140","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0145","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0150","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0155","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0160","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.2515\/therapie\/2010017_bb0165","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.2515\/therapie\/2010017_bb0170","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0b013e3181b2c8cf","article-title":"A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times","volume":"31","author":"Wang","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2010017_bb0175","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jnci\/djn230","article-title":"Disease progression in some cancers may be due to low blood levels of targeted therapies","volume":"100","author":"Tuma","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.2515\/therapie\/2010017_bb0180","first-page":"21","article-title":"M\u00e9thodologie pour l\u2019\u00e9valuation du niveau de preuve du suivi th\u00e9rapeutique pharmacologique","volume":"23","author":"Le Guellec","year":"2009","journal-title":"La Lettre du Pharmacologue"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716306734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716306734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T05:50:44Z","timestamp":1591768244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716306734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0040595716306734"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2010017","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}